Stocks Health care OKYO
NASDAQ · Health careOKYO Pharma Ltd (OKYO)
It posted a net loss of $4.7M. In fiscal 2025 capital spending exceeded operating cash flow by $1.8M. At March 31, 2025 it held $1.6M in cash. Its latest periodic report to the SEC is the annual report (foreign issuer, amended) (20-F/A) filed on August 7, 2026.
What OKYO Pharma Ltd does
OKYO Pharma Ltd is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker OKYO.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$4.7M | -$0.20 | -$1.8M |
| 2024 | n/a | -$16.8M | -$0.57 | n/a |
| 2023 | n/a | -$13.3M | -$0.61 | -$7.7M |
| 2022 | n/a | -$5.4M | -$0.36 | -$5.5M |
| 2022 | n/a | -$3.4M | -$0.32 | -$1.6M |
| 2020 | n/a | -$1.5M | n/a | n/a |
Latest SEC filings
What OKYO Pharma Ltd has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 9, 2026
- September 8, 2026
- August 7, 2026Annual report (foreign issuer, amended) 20-F/A · period to March 31, 2026
- July 28, 2026
- July 27, 2026
- July 23, 2026
- July 23, 2026
- July 22, 2026
- July 22, 2026
- July 22, 2026
Insider trades
What the people running OKYO Pharma Ltd did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
Questions about OKYO
What does OKYO Pharma Ltd do?
OKYO Pharma Ltd is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker OKYO.
Is OKYO Pharma Ltd profitable?
No. In fiscal 2025 it reported a net loss of $4.7M.
When did OKYO Pharma Ltd last report?
Its most recent periodic report is the annual report (foreign issuer, amended) (20-F/A) filed on August 7, 2026. It covers the period to March 31, 2026. Its newest filing of any kind is the foreign issuer update from September 9, 2026.
Similar companies
Compare OKYO with
Follow OKYO
Get an email when OKYO Pharma Ltd files with the SEC: results, executive changes, material agreements and annual reports.
Follow OKYO: get an email when it filesWhere the numbers come from
Financial figures are the values OKYO Pharma Ltd tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.